Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has
led to unprecedented clinical response in a subset of lung cancer patients carrying the …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …